Background
United Therapeutics Corporation (UTC) markets Tyvaso, an inhaled formulation of treprostinil used to treat pulmonary arterial hypertension — a serious, progressive disease affecting blood vessels in the lungs. UTC holds patents covering inhaled treprostinil as a treatment method, including U.S. Patent Nos. 9,593,066 and 10,716,793. Liquidia Technologies sought FDA approval for Yutrepia, a competing inhaled treprostinil product, triggering patent litigation under the Hatch-Waxman Act framework.
The district court found that certain claims of the ‘793 patent were valid and infringed by Liquidia, while claims of the ‘066 patent were invalid as anticipated by prior art. Both sides appealed. Liquidia argued the ‘793 patent claims lacked adequate enablement and written description because the specification did not separately address pulmonary hypertension associated with interstitial lung disease — a distinct patient subgroup. Liquidia also challenged claim construction and infringement findings.
The Court’s Holding
The Federal Circuit affirmed across all contested issues. On enablement and written description, the court rejected Liquidia’s argument that a method-of-treatment patent must separately disclose every variant of the disease covered by the claim. The court held it would be “incorrect to fractionate a disease or condition that a method of treatment claim is directed to” and require individual specification disclosures for each patient subgroup, unless those variants are specifically called out in the claims themselves. This clarification prevents defendants from manufacturing enablement challenges by subdividing a disease into sub-populations not explicitly addressed in the patent specification.
On claim construction, the Federal Circuit agreed with the district court that “treating pulmonary hypertension” does not import FDA safety and efficacy requirements into the patent claims — matters left to regulatory agencies, not patent law. The court also affirmed induced infringement liability based on Liquidia’s labeling, which instructed physicians to prescribe Yutrepia in a manner that would necessarily infringe UTC’s patents. On the ‘066 patent claims found anticipated, the court confirmed that for product-by-process claims, anticipation analysis focuses on whether the prior art discloses the same product, not whether it was made by the same process.
Key Takeaways
- Method-of-treatment patents claiming a broad disease category do not fail enablement or written description simply because the specification does not separately address every recognized subtype or variant of that condition.
- Patent claim scope cannot be narrowed by importing FDA safety and efficacy standards — a treating physician’s need to confirm safety is regulatory, not a patent claim limitation.
- Induced infringement can be established by product labeling that instructs uses constituting infringement, even in a Hatch-Waxman ANDA context.
- Anticipation of product-by-process claims turns on the product itself, not the manufacturing method — prior art disclosing the same product anticipates regardless of how it was made.
Why It Matters
For pharmaceutical and biotech patent holders, the decision provides a meaningful shield against enablement attacks that try to exploit the complexity of disease biology. Plaintiffs in drug patent litigation routinely argue that treatment patents covering broad disease categories fail § 112 because the specification did not study every patient subgroup. The Federal Circuit’s ruling pushes back firmly: patent law does not require a medical encyclopedia covering every disease variant, as long as the specification enables the claimed treatment for the condition as a whole.
The case also reinforces that Hatch-Waxman drug patent litigation is a high-stakes arena where labeling language, claim construction, and § 112 requirements all interact. Pharmaceutical companies seeking FDA approval for competing drugs must carefully draft their product labels to avoid induced infringement exposure, and patent applicants should ensure their specifications broadly enable the claimed treatment without over-fractionating the target disease.